What FDA’s New Biosimilar Development Push Could Mean for Infusion Practices in 2026

The FDA’s recent push to streamline biosimilar development may look like a manufacturer-side story at first glance, but it has real downstream effects for infusion practices.

Recently, the agency issued draft materials clarifying when comparative efficacy studies, some pharmacokinetic work, and switching studies may not be needed. This signals a more efficient biosimilar development pathway without changing the core requirement that approved biosimilars be highly similar to the reference product and have no clinically meaningful differences.

What to Know

• The FDA is trying to remove unnecessary steps from biosimilar development, not weaken scientific standards.
• More efficient development could help bring more biosimilars to market and increase competition across infused biologic categories.
• For infusion practices, the biggest impacts are likely to show up in payer policy changes, formulary movement, reimbursement pressure, patient education, and day-to-day workflow adjustments.
• In provider-administered settings, payer preference often has more immediate operational impact than interchangeability alone.
• Practices that prepare early will be in a stronger position to protect margin, reduce disruption, and support patient confidence during product transitions.

Biosimilars matter because biologics represent a small share of prescriptions but a large share of drug spending, and the FDA continues to prioritize competition. As of March 2026, the agency had approved 82 biosimilars. For infusion practices, that means cost, coverage, and care delivery are becoming more tightly linked.

What the FDA’s Biosimilar Push Means in Plain Operational Terms

In practical terms, the FDA is signaling a less burdensome biosimilar development pathway in some cases, which could attract more developers, expand competition, and increase payer-driven shifts in preferred products. For infusion practices, the operational question is how often they will need to respond to changes in product preferences, coverage, and utilization management as competition grows.

In 2026, practices are unlikely to feel the impact as one dramatic event. More often, it will appear as a series of smaller changes: a payer revises its preferred product, a prior authorization requirement shifts, a reference product loses favored status, or a patient calls with concerns after hearing the term biosimilar.

Why More Biosimilars Matter for Infusion Practices

For in-office infusion providers, the real impact of more biosimilars will likely be felt in the operational and financial decisions that shape daily care delivery.

Payer Policies May Shift More Often

As competition expands, health plans and PBMs may revisit formularies, step-therapy requirements, and prior-authorization criteria more frequently. That can create added work for practice teams responsible for benefit verification, reauthorizations, and treatment access coordination.

Formulary Changes Could Affect Buying and Inventory Strategy

More biosimilars can mean more choice, but only when that choice aligns with coverage and reimbursement. Practices may need to revisit stocking decisions, monitor payer-specific preferences, and avoid products that create administrative friction or reimbursement risk.

Reimbursement Strategy Becomes Critical

In a more competitive biosimilar environment, margin management becomes more complex. Practices need visibility into acquisition costs, reimbursement rates, billing requirements, and payer behavior by plan. Even small gaps between cost and payment can become meaningful at scale, making this a core operational issue for buy-and-bill providers.

Patient Education Will Need to Be Proactive

Patients do not always see product changes as routine. Some may hear the term biosimilar and assume lower quality or reduced effectiveness. That makes proactive, plain-language education especially important when practices are navigating payer-driven product changes. Clear communication can reduce anxiety, support adherence, and help prevent delays caused by confusion or mistrust.

Clinical Workflow Will Need Tighter Coordination

Biosimilar adoption affects scheduling, treatment plan updates, documentation, nursing communication, medication sourcing, financial counseling, and follow-up. Without internal alignment, even small changes in coverage can create avoidable disruption across the care journey.

What Infusion Practices Should Do Now

The smartest response is preparation. Practices do not need to predict every payer move, but they do need a repeatable process for evaluating changes quickly.

That includes monitoring payer updates, reviewing buy-and-bill exposure, aligning internal teams on product policies, and strengthening patient communication tools. It also means treating biosimilar readiness as an ongoing operational capability rather than a one-time project.

How Altus Biologics Helps Practices Adapt

For infusion practices, the recent FDA announcement is only the beginning. The real challenge is translating market movement into operational decisions that protect access, efficiency, and financial performance.

Altus Biologics helps practices navigate that kind of change with a practical understanding of reimbursement, workflow, and patient access. As the biologics landscape becomes more dynamic, practices need more than awareness. They need a partner who understands how policy shifts show up in daily operations and what it takes to adapt without compromising the patient experience.

FAQ

Is the FDA Lowering the Approval Standard for Biosimilars?

No. The FDA is streamlining parts of the development process in some cases, not changing the core approval standard.

Why Should Infusion Practices Care About Biosimilar Development Changes?

A more efficient development pathway could bring more biosimilars to market, affecting payer policy, formulary design, reimbursement strategy, product selection, and patient communication in infusion settings.

Does Interchangeability Matter for Infusion Practices?

Biosimilar interchangeability can matter, but in provider-administered settings, payer preference and coverage policy often have more immediate day-to-day impact than interchangeability alone.

What Should Infusion Practices Focus on in 2026?

Practices should focus on payer monitoring, reimbursement strategy, inventory alignment, staff coordination, and patient education. Those areas are where biosimilar market changes are most likely to create either friction or opportunity.